Status:
COMPLETED
Generalization of Extinction Learning
Lead Sponsor:
University of California, Los Angeles
Conditions:
Social Anxiety Disorder
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
Fear, whether it occurs in humans suffering from an anxiety disorder or in experimental models with rodents, is reduced by exposing the frightened organism to the fearful stimulus in the absence of an...
Eligibility Criteria
Inclusion
- between the ages of 18 and 55,
- fluent in English,
- within normal body weight (BMI=18.5 to 24.9)
- meet DSM-IV diagnostic criteria for Social Phobia and report a fear of public speaking.
Exclusion
- participant report of a diagnosed medical or neurological disorder
- prescription or over the counter medications that can interact with Scopolamine, such as anticholinergic medications (e.g. belladonna alkaloids, antihistamines, meclizine, tricyclic antidepressants, and muscle relaxants), cold medicines, cough suppressants. Other drugs that will be reasons for exclusion include: antimuscarinics, nifedipine, parasympathomimetics, amantadine, amoxapine, antacids, antidiarrheals, anxiolytics, hypnotics, atomexetine, bupropion, cisapride, clozapine, cyclobenzaprine, digoxin, disopyramide, dronabinol (THC), ethanol, maprotilline, memantine, metoclopramide, nabilone, olanzapine, opiate agonists, orphenadrine, phenothiazines, potassium salts, quinidine, sedating H1-blockers, topiramate, tricyclic antidepressants, erthyromycin, ketoconazole, and tegaserod.
- over the counter drugs or substances that may have a sedative effect (e.g. herbal sedatives: ashwagandha, Duboisia hopwoodii, Prostanthera striatiflora, kava, mandrake, valerian, cannabis, passiflora incarnate; Antihistamines: Diphenhydramine, Dimenhydrinate, Doxylamine, Promethazine; Alcohol; Dextromethorphan)
- individuals with urinary problems (e.g., BPH)
- pregnant or nursing females (as the effect of Scop on fetuses is not known)
- suicidality
- delusions or hallucinations
- history of substance dependence in last five years or substance abuse within the past 6 months
Key Trial Info
Start Date :
August 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2017
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT01900301
Start Date
August 1 2013
End Date
August 1 2017
Last Update
October 7 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of California, Los Angeles
Los Angeles, California, United States, 90095